| Cardiac Surgery |
1 |
1 |
| Thromboembolism |
0 |
0.7 |
| Arrhythmia |
0 |
0.67 |
| Hypertension |
0 |
0.67 |
| Myocardial Infarction (MI) |
0 |
0.61 |
| Heart Failure (HF) |
0 |
0.54 |
| Atrial Fibrillation |
0 |
0.52 |
| Electronic Health Record (EHR) |
0 |
0.5 |
| Renal Failure |
0 |
0.49 |
| Clinical Research |
0 |
0.46 |
| Cardiovascular Risk Management |
0 |
0.43 |
| Peripheral Artery Disease |
0 |
0.41 |
| Chronic Kidney Disease |
0 |
0.4 |
| Percutaneous Coronary Intervention |
0 |
0.4 |
| Cardiovascular Imaging |
0 |
0.37 |
| Otolaryngology |
0 |
0.36 |
| Acute Heart Failure (HF) |
0 |
0.33 |
| Cardiomyopathy |
0 |
0.27 |
| Cerebrovascular Accident |
0 |
0.27 |
| COVID-19 |
0 |
0.26 |
| Heart |
0 |
0.26 |
| Surgery |
0 |
0.26 |
| Transcatheter Aortic Valve Replacement |
0 |
0.26 |
| ST Segment Elevation Myocardial Infarction |
0 |
0.24 |
| Lipids Management |
0 |
0.22 |
| Pregnancy |
0 |
0.21 |
| Ablation |
0 |
0.2 |
| Hospital |
0 |
0.2 |
| Pandemic |
0 |
0.2 |
| Perioperative Care |
0 |
0.2 |
| Renal Disease |
0 |
0.19 |
| Electrophysiology |
0 |
0.18 |
| Hyperkalemia |
0 |
0.18 |
| Patient Safety |
0 |
0.18 |
| Acute Myocardial Infarction (MI) |
0 |
0.16 |
| Atherosclerosis |
0 |
0.16 |
| Ventricular Tachycardia |
0 |
0.14 |
| Artery |
0 |
0.13 |
| Blood |
0 |
0.13 |
| Clinical Guidelines |
0 |
0.13 |
| Direct Factor Xa Inhibitor |
0 |
0.13 |
| Ejection Fraction |
0 |
0.13 |
| Exercise |
0 |
0.13 |
| Face |
0 |
0.13 |
| Infarction |
0 |
0.13 |
| Kidney |
0 |
0.13 |
| Pacemaker |
0 |
0.13 |
| Quality of Life |
0 |
0.13 |
| Severe Acute Respiratory Syndrome |
0 |
0.13 |
| Tachycardia |
0 |
0.13 |
| Washington |
0 |
0.13 |
| Acute Respiratory Distress Syndrome |
0 |
0.12 |
| Influenza |
0 |
0.12 |
| C-Reactive Protein (CRP) |
0 |
0.11 |
| Myocardial Infarction (MI) History |
0 |
0.11 |
| PCSK9 |
0 |
0.11 |
| Biologic Therapy |
0 |
0.09 |
| Implantable Cardioverter-Defibrillator |
0 |
0.09 |
| Intravascular Ultrasound |
0 |
0.09 |
| Upper Respiratory Tract Infection |
0 |
0.09 |
| Anticoagulation Therapy |
0 |
0.07 |
| Antihypertensive Agents |
0 |
0.07 |
| Aortic Valve |
0 |
0.07 |
| Beta Blockers |
0 |
0.07 |
| Defibrillator |
0 |
0.07 |
| Diet |
0 |
0.07 |
| Drug and Treatment Safety |
0 |
0.07 |
| Dyslipidemia |
0 |
0.07 |
| Femoral |
0 |
0.07 |
| Grant |
0 |
0.07 |
| Hemodynamics |
0 |
0.07 |
| Hypertrophic Cardiomyopathy |
0 |
0.07 |
| Hypotension |
0 |
0.07 |
| Influenza Vaccine |
0 |
0.07 |
| Liver |
0 |
0.07 |
| Massachusetts |
0 |
0.07 |
| Monoclonal Antibody |
0 |
0.07 |
| Patient History |
0 |
0.07 |
| Preeclampsia |
0 |
0.07 |
| Preventive Screening |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Refractory |
0 |
0.07 |
| Renal Denervation |
0 |
0.07 |
| Resistant Hypertension |
0 |
0.07 |
| Respiratory Tract Infections |
0 |
0.07 |
| Seasonal Influenza |
0 |
0.07 |
| SGLT2 Inhibitor |
0 |
0.07 |
| Shock |
0 |
0.07 |
| Sodium Restriction |
0 |
0.07 |
| South Carolina |
0 |
0.07 |
| Stenosis |
0 |
0.07 |
| Thrombosis |
0 |
0.07 |
| Tricuspid Regurgitation |
0 |
0.07 |
| Ultrasonography |
0 |
0.07 |
| Valve Replacement |
0 |
0.07 |
| Angina Pectoris |
0 |
0.06 |
| Type 2 Diabetes Mellitus |
0 |
0.06 |
| Vaccines |
0 |
0.06 |